首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   435篇
  免费   11篇
  国内免费   3篇
耳鼻咽喉   1篇
儿科学   21篇
妇产科学   1篇
基础医学   14篇
临床医学   31篇
内科学   43篇
神经病学   2篇
特种医学   2篇
外科学   5篇
综合类   91篇
预防医学   17篇
药学   206篇
  3篇
中国医学   12篇
  2022年   3篇
  2021年   13篇
  2020年   11篇
  2019年   8篇
  2018年   6篇
  2017年   10篇
  2016年   7篇
  2015年   12篇
  2014年   31篇
  2013年   41篇
  2012年   48篇
  2011年   29篇
  2010年   25篇
  2009年   18篇
  2008年   8篇
  2007年   15篇
  2006年   12篇
  2005年   14篇
  2004年   12篇
  2003年   9篇
  2002年   7篇
  2001年   5篇
  2000年   8篇
  1999年   6篇
  1998年   7篇
  1997年   10篇
  1996年   9篇
  1995年   5篇
  1994年   6篇
  1993年   11篇
  1992年   4篇
  1991年   3篇
  1990年   5篇
  1989年   2篇
  1988年   2篇
  1986年   1篇
  1985年   2篇
  1984年   4篇
  1983年   1篇
  1982年   1篇
  1981年   3篇
  1980年   1篇
  1979年   1篇
  1978年   2篇
  1977年   2篇
  1976年   1篇
  1975年   2篇
  1974年   1篇
  1973年   2篇
  1971年   1篇
排序方式: 共有449条查询结果,搜索用时 15 毫秒
1.
《中国现代医生》2020,58(17):135-137+147
目的探讨沙丁胺醇联合特布他林治疗支气管哮喘临床疗效及安全性。方法研究共计纳入130例支气管哮喘患者,均为我院2017年3月~2019年2月收治,采取随机数字表法将患者分为常规组与联合用药组,常规组患者予以常规治疗,联合用药组患者给予沙丁胺醇联合特布他林治疗,对比两组患者临床疗效、治疗前后症状积分及治疗后患者咳嗽、呼吸困难及哮鸣音等症状及体征消失时间、患者肺功能指标改善情况及治疗不良反应情况、治疗满意率情况。结果联合用药组治疗有效率高于常规组(P0.05);两组不良反应率均较低(P0.05);治疗后联合用药组患者症状积分优于常规组患者,且患者咳嗽、呼吸困难及哮鸣音等症状及体征消失时间短于常规组患者,肺功能指标优于常规组患者,差异有统计学意义(P0.05);联合用药组患者治疗满意率高于常规组(P0.05)。结论沙丁胺醇联合特布他林治疗支气管哮喘临床疗效均较高,患者症状及肺功能改善,不良反应少,安全可靠,患者满意率高。  相似文献   
2.
BackgroundAlthough the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan. To determine whether the efficacy of low-dose l-isoproterenol was superior to that of salbutamol, we conducted a double-blind, randomized controlled trial.MethodsHospitalized patients aged 1–17 years were eligible if they had severe asthma exacerbation defined by the modified pulmonary index score (MPIS). Patients were randomly assigned (1:1) to receive inhalation of l-isoproterenol (10 μg/kg/h) or salbutamol (500 μg/kg/h) for 12 hours via a large-volume nebulizer with oxygen. The primary outcome was the change in MPIS from baseline to 3 hours after starting inhalation. Trial registration number UMIN000001991.ResultsFrom December 2009 to October 2013, 83 patients (42 in the l-isoproterenol group and 41 in the salbutamol group) were enrolled into the study. Of these, one patient in the l-isoproterenol group did not receive the study drug and was excluded from the analysis. Compared with salbutamol, l-isoproterenol reduced MPIS more rapidly. Mean (SD) changes in MPIS at 3 hours were −2.9 (2.5) in the l-isoproterenol group and −0.9 (2.3) in the salbutamol group (difference −2.0, 95% confidence interval −3.1 to −0.9; P < 0.001). Adverse events occurred in 1 (2%) and 11 (27%) patients in the l-isoproterenol and salbutamol groups, respectively (P = 0.003). Hypokalemia and tachycardia occurred only in the salbutamol group.ConclusionsLow-dose l-isoproterenol has a more rapid effect with fewer adverse events than salbutamol.  相似文献   
3.
目的:探讨射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病(COPD)患者肺功能、生活质量的影响。方法:选择COPD患者90例进行研究,以随机数字表法分为观察组48例和对照组42例。对照组给予沙丁胺醇治疗,观察组在对照组的基础上加用射干麻黄汤治疗。比较两组患者的临床疗效、第1秒用力呼气容积(FEV1)、最大呼气流量(PEF)、用力肺活量(FVC)、生活质量、中医症候积分、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)水平变化情况及不良反应发生情况。结果:治疗后,两组总有效率分别为93.75%、76.19%(P<0.05); 治疗后,两组患者FEV1、PEF、FVC水平均得到显著改善,且观察组高于对照组(P<0.05); 治疗后,两组躯体、认知、情绪、角色、社会功能、总体健康评分水平均得到显著改善,且观察组高于对照组(P<0.05); 治疗后,两组中医症候积分、日间咳嗽积分、夜间咳嗽积分水平显著改善,且观察组低于对照组(P<0.05); 治疗后,两组患者血清IL-6、TNF-α、Hs-CRP水平均得到显著改善,且观察组低于对照组(P<0.05); 观察组不良反应总发生率为10.42%,对照组为16.67%,差异无统计学意义(P>0.05)。结论:射干麻黄汤联合沙丁胺醇治疗慢性阻塞性肺疾病效果显著,可有效改善患者肺功能、生活质量水平。  相似文献   
4.
The present research was aimed to develop and characterize a sustained release dry powder inhalable formulation of salbutamol sulphate. The salbutamol sulphate microparticles were prepared by solvent evaporation method using biodegradable polymer poly (D,L-lactic-co-glycolic acid) to produce salbutamol sulphate microparticle mixed with carrier respirable grade lactose for oral inhalation of dry powder. The drug content were estimated to produce 1 mg sustained release salbutamol sulphate per dose. Total four formulations K1, K2, K3 and K4 were prepared with 1:1, 1:2, 1:3, 1:4 ratio of salbutamol sulphate:poly (D,L-lactic-co-glycolic acid). The developed formulations were studied for physicochemical properties, in vitro drug relase and Anderson cascade impaction studies. The prepared formulations effectively releases drug for 12 h in diffusion bag studies. Based on dissolution performance the 1:1 ratio of salbutamol sulphate:poly (D,L-lactic-co-glycolic acid) produces in vitro release 92.57% at 12 h and having particle size of microparticles (D0.5μm) 5.02±0.6 and the pulmonary deposition of dry powder 34.5±3.21 (respiratory fraction in percentage).  相似文献   
5.
Backgroundβ2-Adrenergic receptor agonists are widely used agents in the treatment of asthma or preterm labor. Since prevalence of asthma was shown to be higher in patients with epilepsy and modulation of noradrenergic system activity may modify epilepsy course, the aim of the present study was to examine the effect of salbutamol (SALB), one of the most commonly used β2-adrenergic receptor agonist on the anticonvulsant potency of four classical antiepileptic drugs (AEDs): valproate (VPA), carbamazepine (CBZ), phenytoin (DPH) and phenobarbital (PB) in mice subjected to the maximal electroshock (MES)-induced seizures.MethodsSeizures were caused by a current delivered through ear-clip electrodes. The influence of AEDs and SALB on animals’ motor coordination and memory processes was also evaluated.ResultsSingle SALB injection did not change, whereas 7 days SALB administration decreased seizure threshold in the MES-induced seizures in mice. Moreover, SALB injected ip for 1 day and for 7 days lowered the antiepileptic activity of PB in the MES-induced seizures in mice, but did not change the effect of other analyzed AEDs: VPA, CBZ or DPH. Butoxamine, a selective β2-adrenergic receptor antagonist, reversed SALB influence on the activity of PB. SALB given alone or in combination with the tested AEDs did not affect animals’ motor performance and memory after both single and 7 days administration.ConclusionsPresented results show that SALB may decrease the antiepileptic efficacy of PB. A special caution is advised to patients with epilepsy receiving β2-adrenergic receptors agonists in the pharmacotherapy of pulmonary and obstetrical disorders.  相似文献   
6.
7.
王平 《黑龙江医学》2012,36(10):756-757
目的观察布地奈德、异丙托溴胺及沙丁胺醇联合采用压缩空气式雾化吸入治疗支气管哮喘的临床疗效。方法将110例支气管哮喘急性发作的患者随机分为两组,治疗组和对照组(每组55例),对照组给予吸氧、输液、肾上腺皮质激素、氨茶碱等常规治疗;治疗组在对照组的基础上加用布地奈德、异丙托溴胺及沙丁胺醇联合采用压缩空气式雾化吸入治疗,比较两组临床症状改善情况。结果治疗组和对照组的总有效率分别为98.2%和76.4%,两组比较差异有显著性(P<0.05)。结论布地奈德、异丙托溴胺及沙丁胺醇联合采用压缩空气式雾化吸入法能迅速及时有效地缓解哮喘发作的症状,挽救生命,方法简便易行,值得临床推广。  相似文献   
8.
ABSTRACT

Objective: This study compared the bronchodilator efficacy and safety of indacaterol with placebo, salbutamol and salmeterol, in patients with persistent asthma, at single therapeutic and supratherapeutic doses.

Research design and methods: This was a randomised, open-label crossover study in adult subjects with asthma (forced expiratory volume in 1 second [FEV1] ≥?60% predicted). In part A, patients (n = 20) received single doses of indacaterol 200?µg, salbutamol 200?µg, salmeterol 50?µg and placebo. In part B, patients (n = 19) received single doses of indacaterol 1000?µg, salbutamol 1000?µg, salmeterol 250?µg and placebo.

Main outcomes measures; Results: For the primary endpoint, FEV1 area under the effect curve during 0–24?h, indacaterol 200?µg was statistically superior to placebo and salbutamol. Indacaterol 200?µg FEV1 was higher than placebo (5?min to 24?h), salbutamol 200?µg (4–24?h), and salmeterol 50?µg (5 and 15?min and 22 and 24?h). Few adverse events were reported; all were mild or moderate in severity. Initial changes were observed in glucose, potassium, heart rate and QTc interval, but all values remained within normal ranges. Values matched placebo levels after a shorter time for indacaterol 1000?µg than for salmeterol 250?µg.

Conclusions: In this single-dose, open-label study, indacaterol 200?µg provided effective 24‐h bronchodilation, with a longer duration than salmeterol 50?µg and a good overall safety profile. The sustained bronchodilation of indacaterol 1000?µg was not associated with sustained systemic adverse effects.  相似文献   
9.
10.
甘盛  施晓光  韩婷  吴超权 《中国药师》2012,15(6):837-840
目的:建立液相-质谱串联法测定人血浆中的沙丁胺醇含量.方法:血浆离心后过玻璃纤维滤膜,经酶解加入氘代沙丁胺醇内标溶液,用C18小柱净化后以3%的氨水甲醇溶液对Oasis MCX小柱进行洗脱,吹干,以0.1%甲酸水溶液-甲醇溶液(95∶5)溶解残余物,用液相质谱串联法测定,以0.1%甲酸乙腈溶液和0.1%甲酸溶液为流动相梯度洗脱.结果:沙丁胺醇在0.25~10.00 μg·kg-1线性关系良好,检出限0.1μg·kg-1.结论:本法灵敏准确、重现性与特异性强、干扰少,可用于人体内沙丁胺醇药动学与生物利用度研究.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号